2-S-cysteinyl-DOPA : An L-tyrosine derivative that is L-DOPA in which the hydrogen at position 2 on the phenyl ring is replaced by a cysteinyl group. Found in the urine of patients with melanoma. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 160007 |
| CHEBI ID | 84296 |
| MeSH ID | M0106345 |
| Synonym |
|---|
| 25565-17-7 |
| 2-s-cysteinyldopa |
| 2-{[(2r)-2-amino-2-carboxyethyl]sulfanyl}-3-hydroxy-l-tyrosine |
| l-tyrosine, 2-((2-amino-2-carboxyethyl)thio)-3-hydroxy-, (r)- |
| 2-s-cysteinyl-3,4-dihydroxyphenylalanine |
| CHEBI:84296 |
| 2-s-cysteinyl-dopa |
| DTXSID80180258 |
| Q27157662 |
| Role | Description |
|---|---|
| human urinary metabolite | Any metabolite (endogenous or exogenous) found in human urine samples. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| catechols | Any compound containing an o-diphenol component. |
| S-organyl-L-cysteine | |
| L-tyrosine derivative | A proteinogenic amino acid derivative resulting from reaction of L-tyrosine at the amino group or the carboxy group, or from the replacement of any hydrogen of L-tyrosine by a heteroatom. |
| aryl sulfide | Any organic sulfide in which the sulfur is attached to at least one aromatic group. |
| amino dicarboxylic acid | |
| diamine | Any polyamine that contains two amino groups. |
| S-conjugate | A bioconjugate containing molecules covalently bonded by a sulphur linkage |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (83.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.19) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||